Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 37

Results For "Emergency"

390 News Found

Centre allocates Rs 267.35 crores to Kerala for Covid response
Policy | August 17, 2021

Centre allocates Rs 267.35 crores to Kerala for Covid response

Rs one crore for each district to create medicine pool and support Centre of Excellence for Telemedicine


Indian pharma’s vaccine opportunity at US $ 10-11 billion
Biotech | August 17, 2021

Indian pharma’s vaccine opportunity at US $ 10-11 billion

Domestic market and developing countries will need doses of Indian vaccines


Novatek Pharma initiates Phase II study of oral COVID-19 drug
Drug Approval | August 14, 2021

Novatek Pharma initiates Phase II study of oral COVID-19 drug

This therapy may provide the first potential oral treatment for COVID-19, recognizing the global emergency of new SARS-CoV-2 variants


Cadila Healthcare net profit at Rs 587.2 cr in Q1FY22
News | August 11, 2021

Cadila Healthcare net profit at Rs 587.2 cr in Q1FY22

The company has also applied to DCGI for Emergency Use Authorization (EUA) for ZyCoVD, the world's first Plasmid DNA Vaccine


INNOVIO QoQ revenues down for the period ended June 30, 2021
Biotech | August 10, 2021

INNOVIO QoQ revenues down for the period ended June 30, 2021

Company working on COVID vaccine INO 4800


Eagle Pharmaceuticals announces licensing agreement for Landiolol
Biotech | August 10, 2021

Eagle Pharmaceuticals announces licensing agreement for Landiolol

Deal signed with AOP Orphan for US commercial rights


Covaxin receives approval from Hungary
Biotech | August 05, 2021

Covaxin receives approval from Hungary

More countries recognise Covaxin


Glenmark signs agreement with SaNOtize to manufacture NONS
News | August 02, 2021

Glenmark signs agreement with SaNOtize to manufacture NONS

The Phase III clinical trial for NONS is expected to be completed by Q4 2021.


Biocon Biologics partners Adagio to manufacture antibody for COVID-19
News | July 27, 2021

Biocon Biologics partners Adagio to manufacture antibody for COVID-19

ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses


Laurus receives license to manufacture and market 2DG
News | July 04, 2021

Laurus receives license to manufacture and market 2DG

2DG has been given emergency approval by the Drug Controller General of India (DCGI) for use on COVID-19 patients in the country